Gilead Sciences and Roche Holding have reportedly sued Indian drugmaker Natco Pharma for theTamiflu generic and they have filed a patent infringement suit in US District Court.
Tamiflu has a market of USD 500 million in the USA. In an interview with CNBC-TV18, Bhaskar Narayana, Finance Director & CFO, Natco Pharma said," When a patent is challenged, the innovator is bound to protect his rights and this can be done only through the mechanism of suing. There is nothing extra-ordinary about it." The litigation process has just started with the suing taking place and will go on for 30 months period, he added. Below is the verbatim transcipt of Narayana's interview with Mitali Mukherjee of CNBC-TV 18. Also watch the accompanying video. Q: Can you just confirm for us first whether this true and what Natco PharmaDiscover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
